In gallbladder cancer, recurrent genetic alterations, particularly KRAS and TP53 mutations, are associated with more aggressive tumor behavior and poorer survival outcomes, underscoring their utility as prognostic biomarkers [33]. This evidence concerns the gene TP53 and gallbladder cancer.